Search clinical trials for: haematologic neoplasms

Total 107550 results

Centre Hospitalier Annecy Genevois

Not yet recruiting

Interpretability of the Quantra® Viscoelastic Test in Patients With Haematological Malignancies With Profound Thrombocytopenia Below 50x10 G/L. (VISCOTHEM-1)

Hematologic Malignancies | Thrombopenia
Assiut University

Not yet recruiting

Characteristics and Outcomes of Patients With Hematological Malignancies

Haematologic Neoplasm
Peking University People's Hospital

Not yet recruiting

Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation

Haematological Malignancy
Rigshospitalet, Denmark

Not yet recruiting

Early Detection of Complications During Immunotherapy for Haematological Malignancy

Hematologic Cancer | CRS - Cytokine Release Syndrome
Shanxi Bethune Hospital

Recruiting

Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

Hematological Malignancy

China
AstraZeneca

Recruiting

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. (PRIMAVERA)

Lymphoma | Hodgkin Lymphoma | Non-Hodgkin

Australia, Korea, Republic of, United Kingdom, Italy, Germany, France, United States, Spain
University Hospital, Toulouse

Recruiting

Feasibility of Physical Activity in Older Adults With Haematological Malignancies: ACCES Study (ACCES)

Geriatric | Haematologic Neoplasm

France
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Melanoma

Spain, Italy, Poland, Brazil, Australia, Chile, Canada, Portugal, Turkey, Germany, Greece, Israel, Sweden, New Zealand, United States, Belgium, France, Taiwan, United Kingdom, Switzerland, South Africa, Denmark, Argentina, Colombia
The Christie NHS Foundation Trust
National Institute for Health Research, United Kingdom

Recruiting

Musculoskeletal Health in Adult Haematological Cancer Survivors (SKETCh)

Lymphoma | Leukemia | Cancer Survivors | Musculoskeletal Complication

United Kingdom
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations (DETERMINE)

Colorectal Neoplasms | Ovarian Neoplasms | Solid Tumor | Gallbladder Neoplasms | Prostatic Neoplasm | Pancreatic Neoplasm | Lung Neoplasm | Haematological Malignancy | Urinary Bladder Neoplasm | Skin Neoplasm | Salivary Gland Neoplasm

United Kingdom
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. (DETERMINE)

Glioma | Melanoma | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Neoplasms by Site | Cancer | Brain Neoplasms | Solid Tumor | Malignant Neoplasm | Malignancy | Haematological Malignancy

United Kingdom
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers (DETERMINE)

Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Neoplasms by Site | Renal Cell Carcinoma | Cancer | Solid Tumor | Anaplastic Large Cell Lymphoma | Neuroblastoma | Malignant Neoplasm | Haematological Malignancy

United Kingdom
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (DETERMINE)

Glioma | Melanoma | Carcinoma, Non-Small-Cell Lung | Multiple Myeloma | Colorectal Neoplasms | Ovarian Neoplasms | Solid Tumor | Thyroid Cancer, Papillary | Thyroid Carcinoma, Anaplastic | Laryngeal Neoplasms | Erdheim-Chester Disease | Haematological Malignancy

United Kingdom
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

Solid Tumor | Haematological Malignancy

United Kingdom
Morten Ladekarl

Recruiting

Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment

Solid Tumor, Unspecified, Adult | Haematological Malignancy

Denmark
Monash University

Recruiting

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension (RATIONALISE)

Hypogammaglobulinemia | Haematological Malignancy

Australia
Hellenic Society of Hematology
GlaxoSmithKline

Not yet recruiting

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Neoplasms | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Multiple Myeloma in Relapse | Gammopathy, Monoclonal | Haematologic Disease
Hellenic Society of Hematology
GlaxoSmithKline

Recruiting

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Neoplasms | Multiple Myeloma | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Gammopathy, Monoclonal | Haematologic Disease | Neoplasm, Plasma Cell

Greece
University Hospital, Lille
Lille University Hospital Emergence Fund

Not yet recruiting

Regional Database for Collecting Clinical-biological and Imaging Data "Secondary Bone Oncology and Bone Localizations of Hematologic Diseases" (OOSLOH)

Bone Metastases
Centre Hospitalier Régional Metz-Thionville
University of Lorraine

Recruiting

APA and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in ICU (APAER_H)

Anxiety | Hematological Malignancies | Relaxation | Adapted Physical Activity

France
RenJi Hospital

Recruiting

Impact of Oral Nutritional Supplements on Patients Undergoing Haematopoietic Stem Cell Transplantation

Haematological Malignancy

China
Assistance Publique - Hôpitaux de Paris

Recruiting

Predictive Markers of Response and Toxicity in Patients With a Haematological Malignancy Treated With Immunotherapy. (PRONOSTIM)

Blood Cancer

France
Centre Hospitalier Universitaire de Nice

Recruiting

Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy (APALLO)

Haematological Malignancy

France
Luzerner Kantonsspital

Recruiting

Prevalence of FID and QoL in Patients With Oncological and With Haematological Malignancies

Functional Iron Deficiency

Switzerland
CytoMed Therapeutics Pte Ltd
National University Hospital, Singapore

Not yet recruiting

Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)

Cancer | Malignancy | Relapsed Cancer | Refractory Cancer

Singapore
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)

Carcinoma, Non-Small-Cell Lung

United States, Australia, Brazil, Chile, China, Costa Rica, Dominican Republic, Germany, Greece, Guatemala, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Spain, Turkey, Portugal, Romania, South Africa, Philippines, Ukr...
Centre Leon Berard

Recruiting

Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation (EVAADE)

Myelodysplastic Syndromes | Severe Combined Immunodeficiency | Acute Leukemia | Haematological Malignancy | Hemoglobinopathy in Children | Bone Marrow Aplasia

France
Hellenic Society of Hematology
GlaxoSmithKline

Recruiting

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Neoplasms | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Gammopathy, Monoclonal | Haematologic Disease

Greece
Malaghan Institute of Medical Research

Recruiting

Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies (THERMAL)

Lymphoma | Leukemia | Myeloma | Temperature Change, Body | Haematological Malignancy

New Zealand
The University of Hong Kong

Recruiting

oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort

Cancer | Graft Vs Host Disease | Haematological Malignancy

Hong Kong
Helsinki University Central Hospital

Recruiting

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)

Solid Tumor | Advanced Cancer | Haematological Malignancy

Finland
Rigshospitalet, Denmark

Recruiting

Muscle Dysfunction in Patients With Haematological Diseases

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hematologic Diseases | Acute Lymphoid Leukemia

Denmark
Prof. Janet Dunn
King's College Hospital NHS Trust; University of Manchester; University of Birmingham and other collaborators

Recruiting

Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes (REPAIR-MDS)

Myelodysplastic Syndromes (MDS)

United Kingdom
University Hospital, Montpellier

Recruiting

Impact of a Sensory Rehabilitation Program on Olfactory-gustatory Alterations in Patients Treated With Chemotherapy for Haematological Cancer (RE-NEZ-SENS)

Lymphoma | Multiple Myeloma | Olfactivo-gustatory Disorder | Haematological Cancer

France
Ospedale San Carlo Borromeo
Associazione Oncologica Milanese AmoLaVita ONLUS

Not yet recruiting

Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies

Cognitive Impairment | Chemo-brain | Haematological Malignancy

Italy
University Hospital Southampton NHS Foundation...
AstraZeneca

Recruiting

Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (REMoDL-A)

Diffuse Large B Cell Lymphoma

United Kingdom
Medical University of Vienna
Roche Pharma AG; Allcyte GmbH

Recruiting

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2)

Refractory Acute Myeloid Leukemia | Advanced Lymphoma | Refractory Lymphoma | Refractory Leukemia | Refractory T-Cell Lymphoma

Austria
The Christie NHS Foundation Trust

Recruiting

Remote Monitoring of Cancer Patients With Suspected Covid-19 (RECAP)

COVID | Oncology | Haematological Malignancy

United Kingdom
Merck Sharp & Dohme LLC

Recruiting

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Melanoma

Spain, Poland, United States, Australia, France, Israel, Italy, South Africa, Switzerland, Chile, Greece, Colombia, Hungary, Argentina
Istituto Scientifico Romagnolo per lo Studio e...
Azienda Unità Sanitaria Locale della Romagna

Recruiting

Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies (INTHEMA)

Haematological Malignancy | Haematologic Disease

Italy
CCTU- Cancer Theme

Recruiting

Metabolic and Immunological Phenotyping in Patients With Cancer (MIPPaC)

Cancer | Non-Hematologic Malignancy

United Kingdom
University Hospital, Caen

Recruiting

Clozapine and Haematologic Malignancies: Observational and Retrospective Study Using the WHO Pharmacovigilance Database (CLOZARIX)

Lymphoma | Leukemia

France
CellCentric Ltd.

Recruiting

Study to Evaluate CCS1477 in Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Non Hodgkin Lymphoma | Peripheral T Cell Lymphoma | Haematological Malignancy | Higher-risk Myelodysplastic Syndrome

United Kingdom, United States, France, Sweden, Spain
University Hospital, Clermont-Ferrand
Fondation Apicil; Association des foulées de la Haute Lozère; Association CEMSBM and other collaborators

Recruiting

Early Palliative Care for Patients With Haematological Malignancies (CALVI)

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Diffuse Large B Cell Lymphoma | Palliative Care

France
Thomas Zilli
University Hospital, Geneva

Recruiting

Total Marrow Irradiation With Volumetric Arc Therapy for Patients Unfit for a 12 Gy TBI

Haematological Malignancy

Switzerland
Karyopharm Therapeutics Inc

Recruiting

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

United Kingdom, United States, Australia, Austria, Belgium, Bulgaria, Canada, France, Germany, Greece, Hungary, India, Israel, Italy, Netherlands, New Zealand, Poland, Serbia, Spain
AstraZeneca
Parexel

Active, not recruiting

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

Advanced Haematological Malignancies

Spain, United States, Canada, Korea, Republic of, Poland, Australia, France, United Kingdom, Ireland
University College, London

Active, not recruiting

CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies

Burkitt Lymphoma | Acute Lymphoblastic Leukemia

United Kingdom
AstraZeneca

Completed

TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause

Hypereosinophilic Syndrome (HES)

United States
AstraZeneca

Terminated

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

Haematological Malignancies

France, Italy, United States, Korea, Republic of, Germany, Australia

Search clinical trials for: haematologic neoplasms

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations